Navigation Links
Cell Genesys to Webcast Third Quarter 2007 Conference Call
Date:10/25/2007

SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's third quarter financial results that will be broadcast live over the internet on Thursday, November 1, 2007, at 2:00 p.m. PT/ 5:00 p.m. ET.

The webcast will be available on the investor relations section of the company's website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's, progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on August 7, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Contact:

Susan Ferris

Investor Relations

650-266-3200


'/>"/>
SOURCE Cell Genesys, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. Visions: Broderick says Wisconsin should be in top third in venture capital
3. Third Wave files countersuit vs. Digene in patent case
4. Third Wave reports net loss of $18.9M for 2006
5. Stratagene to pay Third Wave $10.75M in patent case
6. Third Wave responds to Digene patent lawsuit
7. Third Wave seeks approval of Cystic Fibrosis test
8. Third Wave Technologies to raise $14.9M through private debt
9. Venture capital above $6B for third straight quarter
10. Third Wave reports $5.2M third quarter loss
11. Third Wave reports another loss, stronger sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... new family of 6” modular downlights designed to stay tightly sealed and perform ... areas where damp and wet location listings just aren't enough, such as: hospitals; ...
(Date:8/14/2017)... ... 14, 2017 , ... Every year, millions of dollars are ... community have recently come together to address this antibody crisis and develop standards ... , The team at Thermo Fisher Scientific has arranged for an ...
(Date:8/11/2017)... ... ... A staple in the community for more than 60 years, Bill Miller ... a new digital marketing strategy and updated logo. , As part of the initiative ... the South Texas Blood & Tissue Center for the month of August. , ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):